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Materials and Methods: Type of study : Descriptive study 
24 Eligible patients with age less than 61 years were included in this 
study from October 2011. Informed consent was obtained. Dental 
prophylaxis was carried out in all before the treatment. The patients 
were treated after evaluation and according to the stage of the 
disease. 13/24patients (54.16%) were locally advanced and 11/24 
patients (45.83%) were early stage. All of them received treatment as 
per protocol. Early stages T1/T2 and N0 were treated with EBRT 
(bilateral opposing fields or anterolateral wedge field to face and 
neck) dose of 44 Gy followed by 6 Gy with off cord (total dose 
50Gy/25#) was given to the primary as well as the regional lymph 
nodes of upper neck. This was followed by HDR interstitial 
brachytherapy boost of 2.5Gy per fraction or 3.5Gy per fraction for 6 
fractions twice daily with 6 to 8hrs interval between two fractions. 
Low anterior neck field (for lymph nodes) received 50 Gy per 25 
fractions. Locally advanced T1-T3 with N1, N2a, N2b or T3N0 diseases 
were treated similarly as mentioned above along with concurrent 
chemotherapy Cisplatin (70 mg/m2 every 3 weeks) and 16 Gy Electron 
boost/photon boost (if nodes are involved). Under general 
anaesthesia, trocars and hollow needles were inserted as guide tubes 
in and around the tumour 1cm apart in a single or multiple planes 
through which plastic tubes were threaded. These tubes were then 
secured by buttons. On 2nd post op day patients were simulated with 
CT scan. The CT images were transferred to the treatment planning 
system. The target was delineated in the planning system and 3D 
treatment plan was made to deliver the dose to the target. The effect 
of treatment was assessed by clinical examination as well as by 
imaging techniques if required on follow up. 
Results: High-dose-rate brachytherapy was tolerated by all patients. 
Only 2/24 (0.08%) patients developed bleeding complication. Local 
control was seen in 83.33% of patients among which 9/11 patients 
(81.8%) were in early stage and 11/13 (84.61%) patients were in 
locally advanced stage. (This is an ongoing study.) 
Conclusions: High-dose-rate brachytherapy as a boost for patients 
with primary squamous cell carcinomas of the oral cavity will help 
improve local control. It limits the volume of tissue exposed to high 
doses of radiation therapy. It has showed effective local control in 
early and locally advanced stages. 
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Purpose/Objective: Glomus tumors are rare tumors that are highly 
vascular and typically radiosensitive. Therapeutic options include 
surgery, radiation therapy, embolisation or any combination, but the 
appropriate treatment still remains challenge. The aim of this article 
is to report the results local control of 7 patients with glomus tumors 
treated with surgery and external beam radiotherapy at the Institute 
of Oncology and Radiology of Serbia.  
Materials and Methods: Follow-up was calculated from the date of 
initiation of RT for all patients. Patients had minimum follow-up time 
as 3 years and maximum follow-up as 15 years (mean, 7,14 years, 
median 6,2).The likelihood of local control was analyzed using the 
Kaplan-Meier product limit method. We also analyzed average 
duration of response between two groups of patients with different 
dose of radiation as well as presence of acute and late complications 
of RT.  
Results: Local control was obtained in 85,7% treated patients (6 of 7 
patients). Moreover, local control was achieved in 75% of treated 
patients with recurrent glomus tumors (3 of 4 patients),while in 
patients with residual disease local control was obtained in 100% of 
patients (3 of 3 patients). In our study, patients who received 
radiation therapy with dose less than 50Gy (2patients) had shorter 
average duration of response compared to patients who received 
higher than 50Gy (5 patients). There were no severe treatment 
complications. 
Conclusions: Surgery and radiation therapy are appropriate treatment 
approach for advanced glomus tumors with acceptable complications. 
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Purpose/Objective: The purpose of this retrospective cohort study 
was to identify clinical factors and/or DVH parameters associated with 
acute oral and pharyngeal toxicities (feeding tube, FT rate used as 
surrogate) in head and neck cancer patients treated with definitive 
chemoradiotherapy (CRT). 
Materials and Methods: From 2005-10, 174 patients with unknown 
primary (UKP)(n=18), oropharyngeal (n=122) and nasopharyngeal 
(n=33) squamous cell carcinoma (SCC) were prospectively treated with 
definitive radiotherapy (RT), with or without chemotherapy (CT). 
Median age was 54 years (range, 17-80). One, 13, 31, 107 and 4 
patients presented with stage I, II, III, IVa and IVb disease, 
respectively. Neoadjuvant chemotherapy (CT) was administered in 123 
patients (70%). Cisplatin (Cis) (n=100), carboplatin (Cb) (n=29) or Cis 
followed by Cb (n=20) based CT were given concomitantly with RT. 
Patients were treated with IMRT, delivering 65 Gy in 30 daily fractions 
to PTV1 (macroscopic disease) and 54 Gy in 30 daily fractions to PTV2 
(lymph nodes at risk, or nasopharyngeal mucosa for the UKP cancer 
patients). Reactive as opposed to prophylactic FT insertion policy was 
used. Acute toxicity (NCICTCv.2.0) was recorded prospectively at 
weeks 1–6 during and 1–4 post treatment. Organs at risk potentially 
involved in acute mucosal toxicity and swallowing including the 
superior, middle and inferior pharyngeal constrictor muscles and the 
oral (OM) and pharyngeal mucosae (PM) were delineated on the 
planning CT-scan. Dosimetric and clinical variables including N stage, 
age, gender, type of chemotherapy, smoking status, alcohol 
consumption and RT timing (8-11am vs 11-3pm vs 3-6 pm) were 
entered in a logistic regression analysis. 
Results: Severe acute dysphagia (FT) (Grade 3-4) and severe oral 
mucositis were observed in 85 (49%) and 88 (50%) patients, 
respectively. On univariate analysis, the mean dose to the OM and Cis 
based concomitant CT were significant factors for developing G≥3 oral 
mucositis (p=0.039 and p=0.013, respectively). As expected, patients 
who presented with an UKP SCC developed less G≥3 mucositis 
(p=0,012). These variables remain statistically significant in the 
multivariate analysis. FT rate was also significantly associated with 
the administration of Cis based concomitant CT (50 vs 46%, p=0.045). 
The maximum dose to the OM was also a significant prognostic factor 
for FT. These two variables remain significant in the multivariate 
logistic regression model. A statistical trend was observed, in 
addition, for patients receiving or not cisplatin-5FU induction CT, the 
later presenting less Grade ≥3 acute dysphagia: 55% vs. 41%, 
respectively (p=0.08). None of the other clinical variables mentioned 
above (dose to the constrictors and pharyngealmucosa in particular) 
correlated significantly with FT rates. 
Conclusions: The incidence of acute oral and pharyngeal toxicities 
remain high in head and neck patients treated with CRT. Type of 
chemotherapy and dose distribution to the oral mucosa alone seem to 
be of particular significance. 
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Purpose/Objective: Significant anatomical and volumetric changes 
occur in H&N cancer patients during fractionated radiotherapy (RT). 
The aim of this study was to assess the dosimetric changes and 
investigate its correlation to clinical parameters during a 6 week 
curative course of RT for H&N squamous cancers (HNSCC). 
Materials and Methods: Seventeen patients of HNSCC treated with 
inversed planned image guided IMRT using Tomotherapy Hi-Art was 
selected. The Planning Target volume (PTV) and organs at risk (OARs) 
including bilateral parotids and constrictor muscles were contoured. 
Daily megavoltage CT (MVCT) scans were acquired during treatment as 
per institutional policy; of which ones during fraction 1,15 and 30 was 
used to calculate changes in the dose to the PTV, constrictors and 
parotids. Patient’s weight, mid upper arm circumference (MUAC), mid 
arm muscle circumference (MAMC) and triceps thickness (TS) were 
recorded prior to, midway and at completion of RT (30th fraction). 
Correlation coefficients between the dosimetric and clinical changes 
was calculated to investigate whether it was possible to predict 
dosimetric changes using early clinical variables. 
  
  
  
  
 
  
